Vutrisiran is a medicine used to treat transthyretin amyloidosis, a condition where a protein builds up and damages the nerves or the heart. It is given as a shot under the skin every 3 months. It works by telling the liver to make less of the protein that builds up.
Every report comes from a Lived member, sent anonymously.
Have you tried Amvuttra (Vutrisiran) for Familial Amyloid Neuropathies?
Vutrisiran, sold as Amvuttra, is a prescription injection for transthyretin amyloidosis (ATTR amyloidosis). In this disease a blood protein called transthyretin comes apart and clumps into stiff deposits, called amyloid, that build up in the nerves, the heart or both and gradually stop them working normally. Amvuttra is approved for adults in two situations. The first is polyneuropathy, meaning nerve damage, caused by hereditary ATTR amyloidosis, the inherited form that comes from a change in the transthyretin gene. This nerve damage typically causes numbness, pain or weakness in the feet and hands, and can also disturb blood pressure, digestion and bladder control. The second is cardiomyopathy, a disease of the heart muscle, caused by either the hereditary form or the wild-type form, in which the gene is normal but the protein still forms deposits. For the heart form, its approved goal is to lower the risk of dying from heart causes, of heart-related hospital stays and of urgent visits for heart failure.
Transthyretin is made mainly in the liver, and its normal job is to carry vitamin A and thyroid hormone through the blood. Vutrisiran is a small interfering RNA (siRNA), a short piece of genetic material attached to a sugar tag that steers it into liver cells. Once there, it destroys the instructions the cell uses to build transthyretin, for both the altered and the normal version of the protein. With less transthyretin produced, there is less available to form new amyloid. In the main nerve study, blood transthyretin levels fell by about 83 percent on average. The medicine does not dissolve the damage already done to nerves or the heart; its aim is to slow or halt further harm.
Amvuttra is given as a single injection under the skin, usually in the belly, thigh or upper arm, once every 3 months. The standard dose is the same for everyone, 25 mg in a prefilled syringe, and it is given by a healthcare professional rather than self-injected at home. If an appointment is missed, the dose should be given as soon as possible, and the 3-month schedule then restarts from that new date. Alongside the injections, people are asked to take a daily vitamin A supplement, explained under Interactions & Warnings.
The most common side effects in the clinical trials were pain in the arms or legs, joint pain, shortness of breath and a drop in vitamin A levels. Some of these overlap with symptoms of amyloidosis itself, so new or worsening breathlessness is worth raising with the care team. A small number of people had brief redness, bruising, itching, warmth or pain where the injection was given. Because the medicine lowers vitamin A in the blood, the main specific problem to watch for involves the eyes. Night blindness or new trouble seeing in dim light should be reported to the care team, who may arrange a check with an eye specialist.
Since transthyretin helps carry vitamin A, lowering it also lowers blood vitamin A, by roughly 60 percent in the trials. The label advises taking a supplement that provides the recommended daily amount of vitamin A, and not taking higher doses in an attempt to bring blood levels back to normal. Blood levels during treatment do not reflect how much vitamin A the body actually holds, so a low result is expected and is not a reason to take more. Anyone who is pregnant or planning a pregnancy should tell the prescriber. There is no information on Amvuttra in pregnancy, and the effects on a developing baby of lower transthyretin, lower vitamin A and vitamin A supplements are unknown. It is also unknown whether vutrisiran passes into breast milk. No medicines are known to need avoiding with Amvuttra. It has not been studied in children, in people with severe kidney disease or on dialysis, or in severe liver disease.
Treatment continues with a clinic visit every 3 months for as long as it is judged to be helping. Because it works by preventing new amyloid rather than removing what is already there, progress is usually judged by whether symptoms and test results hold steady rather than by quick improvement. In the nerve study, people on vutrisiran had nerve function, quality of life and walking speed that stayed roughly stable over 9 months, while a comparison group on placebo from an earlier trial got noticeably worse. In the heart study, which followed people for up to 3 years, vutrisiran lowered the combined risk of death and repeated heart-related hospital stays or urgent heart failure visits by about 28 percent relative to placebo over the study period. People also kept more of their walking ability and reported better day-to-day health. About 4 in 10 people in the heart study were already taking tafamidis (Vyndaqel or Vyndamax), a daily pill that holds transthyretin together so it is less likely to form amyloid. Results in that group pointed the same way, but the benefit was smaller and less certain than in people taking vutrisiran alone, so whether to use both together is a question for the specialist. Follow-up usually includes heart or nerve assessments suited to the type of amyloidosis, along with attention to eyesight and vitamin A.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Amvuttra (Vutrisiran), what you've noticed, or ask the community a question.